CD40 and neoplasm: Given the potential negative impact of MEKi on T cell priming in tumor-draining lymph nodes, rational immunotherapy combinations are crucial – e.g., pairing with CD40 stimulation may not be ideal while ICB or certain types of ACT may work very well with MEKi and these early combination trials are very promising.